A new class of aromatase inhibitors has shown promise in tests against breast cancer, but experts are saying tamoxifen, the traditional treatment for the past 20 years, should not be counted out just yet. Tamoxifen might remain the first-line treatment for women with breast cancer, while aromatase inhibitors could become a good backstop for those who cannot tolerate tamoxifen.

Full Story:

Related Summaries